Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.
about
Vascular Remodelling and Mesenchymal Transition in Systemic SclerosisRole of redoximiRs in fibrogenesisMicroRNAs Regulating Signaling Pathways: Potential Biomarkers in Systemic SclerosisSteroidogenesis in the skin: implications for local immune functionsDual mTOR Inhibition Is Required to Prevent TGF-β-Mediated Fibrosis: Implications for SclerodermaA synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responsesAdiponectin is an endogenous anti-fibrotic mediator and therapeutic target.The role of skin trauma in the distribution of morphea lesions: a cross-sectional survey of the Morphea in Adults and Children cohort IVIdentification and characterization of Dicer1e, a Dicer1 protein variant, in oral cancer cells.Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies.Antifibrotic effects of roscovitine in normal and scleroderma fibroblasts.Serum adhesion molecule levels as prognostic markers in patients with early systemic sclerosis: a multicentre, prospective, observational study.mAChRs activation induces epithelial-mesenchymal transition on lung epithelial cellsSustained β-catenin activity in dermal fibroblasts promotes fibrosis by up-regulating expression of extracellular matrix protein-coding genes.FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling.c-Abl silencing reduced the inhibitory effects of TGF-β1 on apoptosis in systemic sclerosis dermal fibroblasts.A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) gene and systemic sclerosisMyofibroblasts in murine cutaneous fibrosis originate from adiponectin-positive intradermal progenitors.Involvement of collagen-binding heat shock protein 47 in scleroderma-associated fibrosis.The Histone Deacetylase Sirtuin 1 Is Reduced in Systemic Sclerosis and Abrogates Fibrotic Responses by Targeting Transforming Growth Factor β Signaling.Fibrosis in systemic sclerosis: common and unique pathobiology.Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts.Association of a rare NOTCH4 coding variant with systemic sclerosis: a family-based whole exome sequencing studyToll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma.Wnt/β-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cellsThe cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathwaysThe adipokine adiponectin has potent anti-fibrotic effects mediated via adenosine monophosphate-activated protein kinase: novel target for fibrosis therapy.Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis.Glycoprofiling as a novel tool in serological assays of systemic sclerosis: a comparative study with three bioanalytical methods.Protective role for miR-9-5p in the fibrogenic transformation of human dermal fibroblasts.Tenascin-C drives persistence of organ fibrosis.Niemann-pick type C2 deficiency in human fibroblasts confers robust and selective activation of prostaglandin E2 biosynthesis.Potential role of human-specific genes, human-specific microRNAs and human-specific non-coding regulatory RNAs in the pathogenesis of systemic sclerosis and Sjögren's syndrome.Early growth response 3 (Egr-3) is induced by transforming growth factor-β and regulates fibrogenic responses.Antifibrotic effects of crocetin in scleroderma fibroblasts and in bleomycin-induced sclerotic mice.Myofibroblasts in Fibrotic Kidneys.Evidence for progressive reduction and loss of telocytes in the dermal cellular network of systemic sclerosisMechanobiological dysregulation of the epidermis and dermis in skin disorders and in degenerationGenistein protects dermal fibrosis in bleomycin-induced experimental sclerodermaRetrospective analysis of the frequency of centrofacial telangiectasia in systemic sclerosis patients treated with bosentan or ilomedin.
P2860
Q26749091-2D625B3A-ADA4-48CA-9008-EB475598F52EQ26776555-61BC535C-FC6A-4034-9A1D-64B32A8E2FD3Q26781257-25293A43-9B85-424B-A4B3-C556739630E9Q26830355-2C772CBE-A486-45B8-B93B-2BE09A667E66Q28264437-CA433C9C-2046-4B3D-93A8-D55F7D9F0401Q33637862-32B5E834-18FB-4088-B341-18C3FEA416D1Q33860888-C496E118-D46C-435C-BE84-3213FC59A416Q34053871-26185E16-49D4-4D0F-99E6-7FE6F11B86A3Q34079194-FE9B75B4-BA92-4E08-9DFE-C66A0CF2256AQ34475490-5DDE8494-B3C3-4F68-BF47-D51CC617C736Q34489708-F4088A3B-F8CE-41FB-ACE3-C85A23D1F9C9Q35091575-02538D37-B2A6-4707-AA73-F3C50CF19F0BQ35134213-9917292E-A219-4D36-984A-505D67D4A3E6Q35171136-8EC76EDC-BA5E-44D8-B76B-77F6BFE5284DQ35551588-6D798B94-9A5D-4564-9149-2FEAC189BB74Q35602670-BA77758D-4395-42DF-BD3A-2595F9CFC6FFQ35623780-6EEAB711-8D2D-4FF3-A22D-3E5121DA37CDQ35755610-8B21E263-05B8-4A7D-8028-F53E6033932DQ35862865-0C8E95C1-393D-46B0-84F7-FC88149E4F2DQ35899944-C4579C47-4380-4A43-A9E2-1F251C36EEF2Q36012572-EED36F86-0626-407B-9B96-CE1336EA1D6EQ36051223-F7C1C63A-DF9A-42FB-A2E8-6AC20D8A6A60Q36187950-C93C1B19-1172-4047-8587-596370A0C221Q36511520-22AE2C74-DD41-4562-B578-E790AB8A7CC5Q36558691-37F2FA4C-4905-41F6-AF1E-9152343545C5Q36591533-FE93B804-1219-4BC7-8557-3D88FD0F8FEAQ36633255-455D234E-4F40-49F8-8B72-EB26F31B731AQ36763871-C0FB7C5A-591B-48E4-99B1-D75FE00CC13EQ36943783-2F90B88D-F62A-4D99-8CBB-3AC95B1628BFQ36965488-EBE037FF-8005-4322-98EB-6957A23E8C02Q36975903-A622EFB2-54B2-4FE6-B61D-AD69C8976248Q37099675-F50D35BA-0ECA-46F3-B8CB-7A7954579808Q37165647-1EB39380-C971-4539-8940-D45008B07E37Q37218781-C87A5089-6B69-48C7-BB58-9FF6DA55D7BDQ37234373-3B131DE1-51FD-4955-9D63-B1845AD05770Q37262528-095A856F-E17A-451D-8C41-370B2E9D21A6Q37294119-A536EC95-F252-492A-A14E-9E2BDD39D17EQ37294709-3A5B59E3-8FA3-44B8-89AB-4E20299812AFQ37305174-561B426E-CB3D-407A-B55D-571EBE2E7875Q37515708-E76ED2D8-C956-40B1-9248-C280BBCBF9D6
P2860
Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 October 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.
@en
Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.
@nl
type
label
Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.
@en
Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.
@nl
prefLabel
Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.
@en
Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.
@nl
P2093
P2860
P356
P1476
Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.
@en
P2093
John Varga
Swati Bhattacharyya
P2860
P2888
P356
10.1038/NRRHEUM.2011.149
P407
P577
2011-10-25T00:00:00Z